$20.00
+1.8%Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
BCAX • NASDAQ
| Bicara Therapeutics Inc. Common Stock Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
OPERATING ACTIVITIES | ||||
-138M | -68M | -52M | -37.8M | |
406K | 56K | 19K | 10K | |
15M | 7.4M | 1.9M | 810K | |
895K | -77K | 14.1M | 0.0 | |
(0.0) | (0.0) | (0.0) | (1K) | |
14.8M | -14.1M | -9.6M | 4.9M | |
-106.8M | -74.8M | -45.6M | -32.1M | |
INVESTING ACTIVITIES | ||||
-280K | -71K | -586K | -192K | |
-318.2M | (0.0) | (0.0) | (0.0) | |
0.0 | 62K | 0.0 | 0.0 | |
-318.5M | -9K | -586K | -192K | |
FINANCING ACTIVITIES | ||||
32.3M | 332.4M | 0.0 | 0.0 | |
0.0 | 1.6M | 149K | 160K | |
32.3M | 334M | 272.5M | 31.7M | |
CASH FLOW SUMMARY | ||||
-393M | 259.3M | 226.3M | -573K | |
489.7M | 230.4M | 4.2M | 4.7M | |
96.7M | 489.7M | 230.4M | 4.2M | |
-107.1M | -74.8M | -46.2M | -32.3M |
BCAX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 21, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | April 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 30, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 19, 2026 | February 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 06, 2025 | 2025 |
Continue your BCAX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.